CIBC World Markets’s Immunovant IMVT Stock Holding History

CIBC World Markets’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-12,880	Closed	-$220K	–	1738
2025 Q1	$220K	Buy	+12,880	New	+$269K	﹤0.01%	1416

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

CIBC World Markets's IMVT Position: Q2 2025 in Review

CIBC World Markets sold out of Immunovant (IMVT) in Q2 2025, closing a stake of 12,880 shares — an estimated $220K sold.

CIBC World Markets first reported a position in IMVT in Q1 2025 and held it in 1 quarter. The position peaked at $220K in Q1 2025. 168 funds tracked by Wall St. Rank hold IMVT as of Q2 2025.

CIBC World Markets reported no remaining Immunovant position as of Q2 2025 after selling out during the quarter.
CIBC World Markets sold 12,880 Immunovant shares in Q2 2025, an estimated $220K.
CIBC World Markets first reported a position in Immunovant in Q1 2025 and held it in 1 quarter.
CIBC World Markets's Immunovant position peaked at $220K in Q1 2025.
168 funds tracked by Wall St. Rank held Immunovant as of Q2 2025.

Based on CIBC World Markets's 13F filing for Q2 2025, filed 14 Aug 2025.